Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. - Wikidata - awgldk - TriplyDB

Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.

Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q37059746

about

Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia The emerging roles of exosomes in leukemogeneis Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective Emerging drugs for chronic myeloid leukemia.Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth.Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell context From Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and Beyond Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis.Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells From bench to bedside: the growing use of translational research in cancer medicine.Bosutinib Therapy Ameliorates Lung Inflammation and Fibrosis in Experimental Silicosis.Targeted therapy of chronic myeloid leukemia.Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors.Philadelphia-positive acute lymphoblastic leukemia: current treatment options Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia.Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.Bosutinib in the management of chronic myelogenous leukemia.Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors.Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia.BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.Matrine inhibits BCR/ABL mediated ERK/MAPK pathway in human leukemia cells.Adhesion structures in leukemia cells and their regulation by Src family kinases.Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action.AHI1 gene expression levels and BCR-ABL1 T315I mutations in chronic myeloid leukemia patients.

P2860

Q24607114-3756314A-F017-4B77-9CF0-8C82C63CFC3E Q26748606-A5DB7D4C-089C-44FD-969F-85F8CFEB2C66 Q27004032-A55D7BB9-C181-43FA-A352-2972DCFF0F58 Q28553277-33D992AB-CB7D-43D2-8E53-FE827C88BE78 Q33536762-3B8578E9-AED2-418C-AC31-D9BE893BA652 Q33623874-C944EE99-9EF3-40A1-977C-6557FFE4B854 Q34251703-CA2BF42B-C0A7-40C6-BD3E-32D6204A2EDD Q34309928-037E64AB-B084-45EA-B32D-E40CFEB299F9 Q34890636-6B6B031F-01E9-4C89-AADC-84BFCB970148 Q34972855-00D3673F-3AAF-4C6D-BE7C-943DAC28F313 Q36533121-AFEA71BA-DF55-4DA2-9CBB-CA91A19439ED Q37116160-AB2F8C46-4108-4F3B-8235-5AD9F16B63DB Q37310478-0FDE08D0-0D71-4F5F-8AF9-914DBBEF5032 Q37450433-25E8C3BD-2D86-4494-BA60-1F72ECA81F04 Q37698244-FA78F31C-E866-4FFB-B05E-20FA20862AF2 Q37699569-7E939145-6AFB-4F5C-B8A3-90B297CCF1E5 Q37752572-8EAB2C10-C901-4EC9-BC69-72D833D27580 Q37810115-AA007E2E-5216-4C1B-9761-1B4A2117CE26 Q37875969-19CE20A7-E7CB-4016-8B09-B2091B8BA9A7 Q38016343-985B1B29-B328-493B-B766-020DE7F69683 Q38050752-C34B916C-72E2-45F7-B973-8E50C3818C3C Q38055491-B60B294F-1136-4C69-9E19-8FE09083EA87 Q38106952-4075D0D8-8C02-42C7-9809-28E36CA9BC6B Q38183422-38FB113B-3465-4E88-A0FF-72DD3D023504 Q38823850-CA35BB25-F871-4A6A-B9A2-28C580E3F927 Q39061903-73E10A4D-B9EC-4FF3-ABE5-D0496F301A2B Q39596672-61A3BE26-C7F6-4782-B91F-52FC3DB5E5DC Q41463339-5039DDC2-E589-4576-86EB-EF642736AEC1 Q46692133-7E141382-36B3-455B-9B49-935584069871 Q47220502-840DC79B-2DA4-4D12-8256-DA253A83140A Q48174522-D551D3EF-9EF5-4707-8A03-0CD9D149881A Q49787703-1678DB01-F023-44A4-9F44-B597F3931D3B Q54333318-9554AB23-3067-4747-99B3-6AADC449C7D9

P2860

Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q37059746

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Src-family kinases in the deve ...... acute lymphoblastic leukemia.

@en

Src-family kinases in the deve ...... acute lymphoblastic leukemia.

@nl

type

label

Src-family kinases in the deve ...... acute lymphoblastic leukemia.

@en

Src-family kinases in the deve ...... acute lymphoblastic leukemia.

@nl

prefLabel

Src-family kinases in the deve ...... acute lymphoblastic leukemia.

@en

Src-family kinases in the deve ...... acute lymphoblastic leukemia.

@nl

P1433

Q37059746-3578FAE6-83FC-4FB7-9E24-C38839ADCA38

P1476

Q37059746-69A4A3FC-084D-466D-A803-1CEF5A89CDCC

P2093

Q37059746-E6FBD422-14D8-4B23-A262-8B0C77CB945E

P275

Q37059746-F87AAD09-CFA2-40F9-9FB0-7E6741CE63A1

P2860

Q37059746-0764580E-9E31-4D40-A1C6-9CE187B225B0

Q37059746-09785F25-C8CC-495B-A74F-907A78BA7ABC

Q37059746-0F9365D2-1C3C-46EC-B9D2-E19306F9BC92

Q37059746-113794E5-4F6F-4B5D-91CB-F0C001F05EFE

Q37059746-113937C7-A886-4FC9-A160-682D1E9A3C75

Q37059746-12EEDA77-313C-41B2-92A5-EE157EB5F6F5

Q37059746-1871749E-7CB5-441D-A21D-B72F2BCE885A

Q37059746-19A3F176-1F5B-49BB-93F5-2360B773E316

Q37059746-1FF91BDD-E282-44E4-B909-6A80B1D9D242

Q37059746-27017A49-327A-453F-9EDC-EE44ADD8CE1A

P304

Q37059746-3B2260AF-A48E-4095-A1B5-3B30F946DEA1

P31

Q37059746-0DD0F259-A850-423E-8CEE-8119420CC1C1

Q37059746-AC4566A6-D807-411C-BE25-388236CDD807

P356

Q37059746-4BFC1723-17FD-4D3D-8443-AF59B96AE33D

P433

Q37059746-DFFA10CE-F08E-4E6C-B126-57494D786066

P478

Q37059746-30FC9EC8-8C32-41D0-855F-EED4202F1847

P5008

Q37059746-CE76DFCA-25F4-47EA-BF96-6414FE90263A

P577

Q37059746-B4502568-66F4-4979-8253-C0346D3C0AB8

P5875

Q37059746-CDE4BE03-EDCA-494E-9EFC-A4C8753AE553

P698

Q37059746-1B85F705-934B-4691-838F-B09701FFCF53

P921

Q37059746-074007E1-1963-4475-8EF1-D2614B266E0F

Q37059746-4C175A38-91D2-40FF-BEA5-6459B9D7AC3F

Q37059746-67DCB8C9-264D-4FAC-9D22-666C909A8A22

Q37059746-DB0C7B40-A42B-4743-B2B0-BA7478CEEC8F

Q37059746-E001CDDA-F1AE-4588-8913-44F12C043299

P932

Q37059746-77DBA13A-A7D8-46C3-8BF8-BD3AE37DF6D4

P356

10428190701713689

P1433

Leukemia & Lymphoma

P1476

Src-family kinases in the deve ...... acute lymphoblastic leukemia.

@en

P2093

Shaoguang Li

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation

Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway

STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells.

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)

Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr

Two distinct phosphorylation pathways have additive effects on Abl family kinase activation

P304

19-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428190701713689

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5648566

http://www.w3.org/2001/XMLSchema#string

P698

18203007

http://www.w3.org/2001/XMLSchema#string

P921

precursor lymphoblastic lymphoma/leukemia

chronic myeloid leukemia

Src family kinase

P932

2430171

http://www.w3.org/2001/XMLSchema#string